Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Thiazolidinediones on Treating Nonalcoholic Fatty Liver Disease: A Network Meta-Analysis
People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take it
Clinical trial data shows only 4.2% of participants discontinued due to side effects after week 24
Noninsulin glucose-lowering agents currently used to treat T2D in the USA include biguanides, sulfonylureas, thiazolidinediones, -glucosidase inhibitors, meglitinides, dipeptidyl peptidase 4 inhibitors (DPP4is), sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists, bile acid sequestrants, dopamine-2 agonists, and amylin mimetics [3]
US$ 28.38
US$ 24.07
US$ 23.34
US$ 21.37
US$ 21.95
US$ 25.42
US$ 21.72
US$ 25.15
US$ 24.10
